European Journal of Haematology

Article	Citations
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care	109
A new reliable and highly specific monoclonal antibody to detect the C‐terminal region of silencer of cytokine signaling 1	45
Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real‐world findings from the International Paroxysmal Nocturnal He	42
Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients	40
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study	38
Issue Information	35
Haematology Outcomes Network in Europe (HONEUR)—A collaborative, interdisciplinary platform to harness the potential of real‐world data in hematology	31
Issue Information	27
Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies	26
ABO Blood Type and Short‐Term Mortality in Patients With Infection‐Associated Disseminated Intravascular Coagulation	25
Distance to CAR‐T Treatment Center Does Not Impede Delivery	24
Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations	23
Bone marrow CD3+CD56+ regulatory T lymphocytes (TR3−56 cells) are inversely associated with activation and expansion of bon	23
Lymphoid malignancy in common variable immunodeficiency in a single‐center cohort	22
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies	21
Issue Information	20
Persistent opioid use in patients with multiple myeloma post‐ASCT	20
Issue Information	20
Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia	19
	19
	19
Insulin‐like growth factor‐1 and insulin‐like growth factor binding protein‐3: impact on early haematopoietic reconstitution following allogeneic haematopoietic stem cell transplantation	18
	18
Effect of pre‐transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis	18
Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia	17

Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data	17
Trajectories of the SARS‐CoV‐2 RNA load in patients with hematological malignancy	17
Busulfan and cyclophosphamide‐based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion‐dependent thalassem	15
Validation of National Early Warning Score and Quick Sequential (sepsis‐related) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemothe	15
	15
Issue Information	14
Prognostic value of the mutation types and dynamics of FLT3‐ITD in acute myeloid leukemia	14
Issue Information	14
C3+ and C3− warm autoimmune hemolytic anemias: A comparison of clinical characteristics and treatment outcomes	14
Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemoth	14
Safety of outpatient stem cell mobilization with low‐ or intermediate‐dose cyclophosphamide in newly diagnosed multiple myeloma patients	13
Healthcare‐associated blood stream infections in hematological patients in Finland during the years 2006‐2016	13
Internet‐based patient survey on the consequences of COVID‐19 lockdown on treatment and medical follow‐up of patients with aplastic anemia or paroxysmal nocturnal hemoglobinuria in Germany	13
MCIR1: A patient‐derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance	13
Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia	13
	12
	12
Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry	12
Issue Information	12
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma	11
The evolution of immune dysfunction in multiple myeloma	11
Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada	11
	11
Allogeneic hematopoietic stem cell transplantation in patients with therapy‐related hematologic malignancies developing after multiple myeloma	11
MDS/CMML from resource‐limited region: Characteristics and comparison to tertiary reference European center	11
Prothrombin consumption as an indicator of hemorrhagic phenotype in mild platelet function disorders	11
Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study	11
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review	10
	10
Validation of the GATMO score in predicting non‐relapse mortality following hematopoietic cell transplant in multiple myeloma patients	10
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy	10
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation	10
Adaptive functioning and academic achievement in pediatric survivors of acute lymphoblastic leukemia: Associations with executive functioning, socioeconomic status, and academic support	10
Issue Information	10
CAR‐T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation	9
Fix low dose venetoclax‐azacitidine treatment of unfit acute myeloid leukemia patients	9
Efficacy of Helicobater pylori eradication in patients with diffuse large B‐cell lymphoma of the stomach: A systematic review	9
Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States	9
Prognostic impact and risk factors of cancer‐associated thrombosis events in stage‐IV cancer patients treated with immune checkpoint inhibitors	9
Adverse impact of a highCD4/CD8ratio in the allograft may be overcome by methotrexate‐ but not mycophenolate‐ or post‐transplant cyclophosphamide‐based graft versus host disease	9
The role of oral iron in the treatment of adults with iron deficiency	9
Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population‐based cohort study	9
A systematic review of the literature on localized gastrointestinal tract amyloidosis: Presentation, management and outcomes	9
Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first‐line treatment for patients with diffuse large B‐cell lymphoma	8
Non‐driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia	8
Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real‐world Swedish population receiving modern treatment	8
The ektacytometric elongation Index (EI) of erythrocytes, validation of a prognostic, rheological biomarker for patients with sickle cell disease	8
	8
Issue Information	8
Appropriateness of inpatient intravenous iron therapy in a Swiss tertiary care hospital	8

Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long‐term results of the p	7
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes	7
The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera	7
A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	7
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia	7
Effectiveness of progressive moderate‐vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with hemophilia: Secondary analysis of a randomized	7
A 3′ tRNA‐derived fragment produced by tRNALeuAAG and tRNALeuTAG is associated with poor prognosis in B‐cell chronic lymphocytic leukemia, independently of classical prognostic f	7
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis	7
Issue Information	7
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma	7
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea	7
5′‐nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate‐risk cytogenetics	7
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia	7
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study	7
Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry	7
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect	7
Recombinant factor IX Fc for the treatment of hemophilia B	7
The role of opportunistic quantitative computed tomography in the evaluation of bone disease and risk of fracture in thalassemia major	7
Issue Information	7
Multistep pathogenesis of chronic myelomonocytic leukemia in patients	7
Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions	6
	6
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter inte	6
The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy re	6
Evaluation of soluble P‐selectin as a predictive biomarker in acute symptomatic pulmonary embolism: Insights from a prospective observational study	6
Sequence matters: Total body irradiation (TBI)‐based myeloablative conditioning with post‐transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophospha	6
Long‐term survivorship care after CAR‐T cell therapy	6
Direct Oral Anticoagulants in Budd‐Chiari Syndrome	6
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes	6
Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3‐ITD positive AML	6
Assessing patient attitudes toward genetic testing for hereditary hematologic malignancy	6
Bone metabolism parameters and their relation to cytogenetics in multiple myeloma	6
Circulating endothelial cells and endothelial progenitor cells as potential predictors of acute GVHD after allogeneic hematopoietic stem cell transplantation	6
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy	6
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway	6
Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma	6
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes	6
Immune thrombocytopenic purpura secondary to COVID‐19 vaccination: A systematic review	6
Racial and ethnic differences in sickle cell disease within the United States: From demographics to outcomes	6
Enhancing thalassemia gene carrier identification in non‐anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning	6
Featured Cover	6
Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL	6
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies	6
Optimized GVHD Prevention in HLA‐Mismatched Unrelated Allogeneic HCT Using a PTCY‐Based Approach	6
An artificial intelligence‐driven predictive model for pediatric allogeneic hematopoietic stem cell transplantation using clinical variables	6
Letter to the Editor: Fine‐needle aspiration cytology and core‐needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement	6
White blood count, D‐dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID‐19 patients: The French multicenter CLOTVID retrospecti	6
Development and Clinical Validation of Liquid Chromatography–Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid‐Refractory Graft‐Versus‐Host Disease: A First Step Towards Optimized Treatmen	6
Favourable Outcome of Relapsed PCNSL Among Transplant Eligble Patients	5
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients	5
A Pilot Study Assessing the Accuracy of AI ChatGPT Responses for AL Amyloidosis	5
Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia	5
Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (ATG) Based GVHD	5
High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R‐CHOP in diffuse large B cell lymphoma	5
Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients	5
Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis	5
Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late‐stage erythropoiesis	5
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre‐ibrutinib era: A population‐based study	5
Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting	5
Health‐Related Quality of Life During Carfilzomib–Lenalidomide–Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study	5
Impact of Gut Microbiota and Inflammatory Cytokines on Immune Thrombocytopenia	5
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement	5
Long‐term clinical outcomes and healthcare utilization of sickle cell disease patients with COVID‐19: A 2.5‐year follow‐up study	5
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg	5
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose	5
Incidence, prognostic factors, and survival outcomes in patients with blastic plasmacytoid dendritic cell neoplasm: A retrospective study in the Surveillance, Epidemiology, and End Results database	5
The current challenges faced by people with hemophilia B	5
Long‐term effectiveness of eculizumab: Data from the International PNH Registry	5
Hematologic Complications of Pregnancy	5
The Effect of the Pre‐Transplant Disease Status on the Outcome for Recipients of T‐Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas	5
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study	5
Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia	5
Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia	5
Long‐term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real‐world setting	5
Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity	5
Issue Information	5
Plasma monomeric ApoA1 and high‐density lipoprotein bound ApoA1 are markedly decreased and associated with low levels of lipophilic antioxidants in sickle cell disease: A potential new pathway for the	5
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial	5
Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)	4
Co‐existence of chronic lymphocytic leukemia and chronic myeloid leukemia and underlying pathogenetic mechanisms	4

Patients with aggressive B‐cell lymphoma receiving CAR T‐cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis	4
Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients	4
Determinants of durable humoral and T cell immunity in myeloma patients following COVID‐19 vaccination	4
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine	4
Transfusion requirements and complication rate in β‐thalassemia intermedia due to heterozygous β‐globin gene mutation and triplicated α‐globin genes	4
	4
T cell–mediated autoimmunity in immune thrombocytopenia	4
Treatment horizon in multiple myeloma	4
Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogene	4
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study	4
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients fr	4
Cytogenetic and molecular characteristics and outcomes of adult patients with early T‐cell precursor acute lymphoblastic leukemia	4
Resveratrol and tetrahydroisoquinoline effects on neutrophil sensitivity to NETosis formation in low‐risk essential thrombocythemia patients	4
Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma—A Retrospective Multicenter Analysis	4
Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma	4
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups	4
Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T‐cell leukemia	4
Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis	4
Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts	4
Highly expressed genes in multiple myeloma cells – what can they tell us about the disease?	4
Determinants of outcomes and advances in CD19‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia	4
Issue Information	4
Issue Information	4
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries	4
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?	4
Cell‐free DNA levels are increased in acute graft‐versus‐host disease	4
Long‐term outcome in patients with mantle cell lymphoma following high‐dose therapy and autologous stem cell transplantation	4
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	4
High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma	4
Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry	4
	4
Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation	4
In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression	4
The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark: Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment	4
Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH‐depe	4
Comparison of HiDAC Versus FLAG‐IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High‐Risk Myelodysplastic Syndrome	4
Risk factors for invasive fungal infection in 5‐azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome	4
Screening for occult cancer after unprovoked venous thromboembolism: Assessing the current literature and future directions	4
Issue Information	4
PD‐L1 expression predicts efficacy in the phase II SPiReL trial with MVP‐S, pembrolizumab, and low‐dose CPA in R/R DLBCL	4
Psychological toxicity in classical hematology	4
	4
Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients	3
Relationship between hemoglobin, hemolysis, and transcranial Doppler velocities in children with sickle cell disease: Results from a long‐term natural history study in Italy in the era of multimodal t	3
A diagnostic challenge—First case of chronic lymphatic leukemia‐associated necrotizing sweet syndrome	3
Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review	3
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma	3
Association of iron infusion reactions with ABO blood type	3
Novel biomarkers to identify complicated course of febrile neutropenia in hematological patients receiving intensive chemotherapy	3
Clinical and pathological features of clonal cytopenia of undetermined significance presenting with isolated thrombocytopenia (CCUS‐IT)	3
Cover Image	3
The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center	3
Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high‐grade B‐cell lymphoma	3
Up‐front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra‐nodal NKT cell lymphoma: A multicenter real‐world study in Ch	3
Predictors for and outcomes after bone marrow biopsy in Scandinavian patients with chronic immune thrombocytopenia	3
Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single‐center, retrospective study	3
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France	3
Identification of the molecular etiology in rare congenital hemolytic anemias using next‐generation sequencing with exome‐based copy number variant analysis	3
Hybrid immunity to SARS‐CoV‐2 in patients with chronic lymphocytic leukemia	3
Adherence to 6‐Mercaptopurine (6‐MP) and Habit Strength in Pediatric Acute Lymphoblastic Leukemia (ALL)	3
Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen	3
Influence of conditioning regimen intensity on outcomes post‐allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission	3
Pancreas‐related persisting sequelae in ALL survivors with a history of asparaginase‐associated pancreatitis: A part of the ALL‐STAR study	3
Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution	3
Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults	3
Cytokine gene polymorphisms are associated with response to blinatumomab in B‐cell acute lymphoblastic leukemia	3
Assessment of agreement between EXTEM and NATEM thromboelastometry measurement assays in critically ill neonates	3
Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept	3
Generic Lenalidomide: An opportunity to address the balance of administrative burden and drug safety	3
Impact of hypoalbuminemia on the prognosis of relapsed/refractory B‐cell lymphoma treated with axicabtagene ciloleucel	3
	3
A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience	3
Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data	3
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study	3
Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival	3
Response to “Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease: Comment”	3
TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study)	3
The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma	3
Standardization for obtaining blood viscosity: A systematic review	3
Issue Information	3
Real‐world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan	3
Tandem bispecific CD123/CLL‐1 CAR‐T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia	3
Impact of cytomegalovirus (CMV) seroconversion pre‐allogeneic hematopoietic cell transplantation on posttransplant outcomes	3
	3
Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors	3
Venous thromboembolism prophylaxis in hospitalized sickle cell disease and sickle cell trait patients	3
Validation of patient‐reported vaso‐occlusive crisis day as an endpoint in sickle cell disease studies	3
Real‐world treatment patterns in patients initiating third‐line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain	3
	3
Comparison of telomere length in patients with bone marrow failure syndromes and healthy controls	3
Whole‐exome sequencing identifies functional classes of gene mutations associated with bone marrow failure in pediatric Fanconi Anemia patients	3
HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B‐cell acute lymphoblastic leukemia	3
Important questions for the malignant hematologist to consider when designing or evaluating a study with patient‐reported outcome measures (PROMs)	3
Outcomes of coronavirus disease 2019 (COVID‐19) and risk factors associated with severe COVID‐19 in patients with mature B‐cell non‐Hodgkin lymphomas: A US electronic health record cohort study	3
Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria	3